🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Placebo for AG-946 oral tablet., AG-946, AG-946

    Lacuna Pharma Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  2. Placebo for MRM-3379, MRM-3379, MRM-3379

    Lacuna Pharma Pty Ltd

    ​​Fragile X Syndrome​

    phase 2 small molecule active

    1 trial

  3. Placebo for TransCon CNP, TransCon CNP 3.9 mg CNP-38/vial, Navepegritide 2.8 mg CNP(89-126), Navepegritide 1.3 mg CNP(89-126)

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  4. Placebo for petrelintide, Petrelintide, Petrelintide

    Zealand Pharma A/S

    Weight management

    phase 2 small molecule active

    1 trial

  5. Placebo is identical with the test product and just does not contain active substance.

    Lacuna Pharma Pty Ltd

    Prurigo Nodularis

    phase 2 small molecule active

    1 trial

  6. Placebo matching REGN9933, REGN7508, REGN9933, Placebo matching REGN7508

    Lacuna Pharma Pty Ltd

    Venous Thromboembolism

    phase 2 small molecule active

    1 trial

  7. Placebo matching with ZED1227 capsules of Dr. Falk Pharma GmbH, CEC02, CEC03

    Dr. Falk Pharma GmbH

    Celiac Disease

    phase 2 small molecule active

    1 trial

  8. Placebo of Dexamfetamine sulfate 20 mg modified-release capsule, Dexamfetamine sulfate 20 mg modified-release capsule, Attentin 5 mg, Tablette, Dexamfetamine sulfate 15 mg modified-release capsule, Dexamfetamine sulfate 10 mg modified-release capsule, Placebo of Attentin 5 mg 10 mg tablets, Placebo of Dexamfetamine sulfate 15 mg modified-release capsule, Attentin 10 mg Tablette, Placebo of Dexamfetamine sulfate 10 mg modified-release capsule

    Lacuna Pharma Pty Ltd

    Adults with ADHD and moderate to severe depression

    phase 2 small molecule active

    1 trial

  9. Placebo of NAL, NACYSTELYN

    Laboratoire HRA Pharma

    Obstructive Sleep Apnea

    phase 2 small molecule active

    1 trial

  10. Placebo of leflunomide, Arava 20 mg film-coated tablets, Mycophenolate mofetil Teva 500 mg film-coated tablets, Placebo of mycophenolate mofetil, Placebo of hydroxychloroquine, PLAQUENIL 200 mg, comprimé pelliculé

    Pari Pharma GmbH

    Primary Sjogren's syndrome

    phase 2 small molecule active

    1 trial

  11. Placebo solution for injection matching COR-1167, COR-1167

    Lacuna Pharma Pty Ltd

    Worsening Heart Failure

    phase 2 small molecule active

    1 trial

  12. Placebo sterile solution for SC injection, Obexelimab

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  13. Placebo to BYL719 50 mg film-coated tablets (Light Yellow) Placebo to BYL719 125 mg film-coated tablets (Dark Yellow), BYL719, BYL719, BYL719, BYL719, BYL719

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  14. Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant

    Lacuna Pharma Pty Ltd

    Tuberous Sclerosis Complex

    phase 2 small molecule active

    1 trial

  15. Placebo to LTP001 00mg hard gelatin capsule, LTP001, LTP001, Placebo to LTP001 00mg hard gelatin capsule

    Novartis Pharmaceuticals

    Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  16. Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  17. Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230

    Novartis Pharmaceuticals

    Calcific Aortic Valve Stenosis

    phase 2 small molecule active

    1 trial

  18. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  19. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1

    phase 2 small molecule active

    1 trial

  20. Placebo to match ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  21. Placebo to match IMP TEV-56286, Emrusolmin

    Lacuna Pharma Pty Ltd

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  22. Placebo to match buloxibutid oral capsules, Buloxibutid

    Lacuna Pharma Pty Ltd

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  23. Placebo, EP262, -, EP262

    Lacuna Pharma Pty Ltd

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  24. Placebo, Vacuna Phleum pratense 3000 TBU/ml, Vacuna Phleum pratense 1000 TBU/ml, Test de provocación nasal Phleum pratense, Vacuna Phleum pratense 6000 TBU/ml

    Lacuna Pharma Pty Ltd

    Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources